Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

367 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Adherence to highly active antiretroviral therapy is better in patients receiving non-nucleoside reverse transcriptase inhibitor-containing regimens than in those receiving protease inhibitor-containing regimens.
Trotta MP, Ammassari A, Cozzi-Lepri A, Zaccarelli M, Castelli F, Narciso P, Melzi S, De Luca A, Monforte AD, Antinori A; Adherence Italian Cohort Naive Antiretrovirals (AdICONA) Study Group; Adherence Spallanzani (AdeSpall) Study Group. Trotta MP, et al. AIDS. 2003 May 2;17(7):1099-102. doi: 10.1097/00002030-200305020-00026. AIDS. 2003. PMID: 12700467
When to start highly active antiretroviral therapy in chronically HIV-infected patients: evidence from the ICONA study.
Cozzi Lepri A, Phillips AN, d'Arminio Monforte A, Castelli F, Antinori A, de Luca A, Pezzotti P, Alberici F, Cargnel A, Grima P, Piscopo R, Prestileo T, Scalise G, Vigevani M, Moroni M; ICONA Study Group. Cozzi Lepri A, et al. AIDS. 2001 May 25;15(8):983-90. doi: 10.1097/00002030-200105250-00006. AIDS. 2001. PMID: 11399980 Clinical Trial.
Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy.
Perno CF, Cozzi-Lepri A, Balotta C, Forbici F, Violin M, Bertoli A, Facchi G, Pezzotti P, Cadeo G, Tositti G, Pasquinucci S, Pauluzzi S, Scalzini A, Salassa B, Vincenti A, Phillips AN, Dianzani F, Appice A, Angarano G, Monno L, Ippolito G, Moroni M, d' Arminio Monforte A; Italian Cohort Naive Antiretroviral (I.CO.N.A.) Study Group. Perno CF, et al. J Infect Dis. 2001 Oct 15;184(8):983-91. doi: 10.1086/323604. Epub 2001 Aug 30. J Infect Dis. 2001. PMID: 11574912
Intermittent and sustained low-level HIV viral rebound in patients receiving potent antiretroviral therapy.
Greub G, Cozzi-Lepri A, Ledergerber B, Staszewski S, Perrin L, Miller V, Francioli P, Furrer H, Battegay M, Vernazza P, Bernasconi E, Günthard HF, Hirschel B, Phillips AN, Telenti A; Frankfurt HIV Clinic Cohort and the Swiss HIV Cohort Study. Greub G, et al. AIDS. 2002 Sep 27;16(14):1967-9. doi: 10.1097/00002030-200209270-00017. AIDS. 2002. PMID: 12351960 No abstract available.
Incidence of adipose tissue alterations in first-line antiretroviral therapy: the LipoICoNa Study.
Galli M, Cozzi-Lepri A, Ridolfo AL, Gervasoni C, Ravasio L, Corsico L, Gianelli E, Vaccarezza M, Vullo V, Cargnel A, Minoli L, Coronado O, Giacometti A, Antinori A, Antonucci G, D'Arminio Monforte A, Moroni M; LipoICoNa Study. Galli M, et al. Arch Intern Med. 2002 Dec 9-23;162(22):2621-8. doi: 10.1001/archinte.162.22.2621. Arch Intern Med. 2002. PMID: 12456235
Virologic correlates of adherence to antiretroviral medications and therapeutic failure.
Perno CF, Ceccherini-Silberstein F, De Luca A, Cozzi-Lepri A, Gori C, Cingolani A, Bellocchi MC, Trotta MP, Piano P, Forbici F, Scasso A, Vullo V, d'Arminio Monforte A, Antinori A; AdICoNA Study Group. Perno CF, et al. J Acquir Immune Defic Syndr. 2002 Dec 15;31 Suppl 3:S118-22. doi: 10.1097/00126334-200212153-00006. J Acquir Immune Defic Syndr. 2002. PMID: 12562033 Review.
367 results